CUTISS AG’s Post

Lipid hard exudates can be particularly challenging in our patients with diabetic macular edema. A big thank you to Healio | Ocular Surgery News and Anthony DeFino and Eamon Dreisbach for covering our research looking at the efficacy of #faricimab in resolving hard exudates in the pivotal #yosemite and #rhine trials of patients with #DiabeticMacularEdema and #DiabeticRetinopathy. Kara Gibson PhD Manuel Amador, MD Florie Mar, PhD https://lnkd.in/ga-y9GHGVIDEO: Faricimab shows greater reduction in hard exudates in patients with DME

Lipid hard exudates can be particularly challenging in our patients with diabetic macular edema. A big thank you to Healio | Ocular Surgery News and Anthony DeFino and Eamon Dreisbach for covering our research looking at the efficacy of #faricimab in resolving hard exudates in the pivotal #yosemite and #rhine trials of patients with #DiabeticMacularEdema and #DiabeticRetinopathy. Kara Gibson PhD Manuel Amador, MD Florie Mar, PhD https://lnkd.in/ga-y9GHG

Lipid hard exudates can be particularly challenging in our patients with diabetic macular edema. A big thank you to Healio | Ocular Surgery News and Anthony DeFino and Eamon Dreisbach for covering our research looking at the efficacy of #faricimab in resolving hard exudates in the pivotal #yosemite and #rhine trials of patients with #DiabeticMacularEdema and #DiabeticRetinopathy. Kara Gibson PhD Manuel Amador, MD Florie Mar, PhD https://lnkd.in/ga-y9GHG 

🚀 HistoSonics, Inc. Secures $102M Series D Funding, Paving the Way for a New Era in Non-Invasive Surgery 🚀 Histotripsy is a technology that uses sound energy to precisely target and destroy tissue without incisions, radiation, or heat. This means patients can undergo treatment with minimal recovery time, reducing the risks and complications associated with other surgical methods. Their Edison platform is very impressive and at SRS earlier this year the booth was a crowded place with an impressive demo. As the global population ages, the demand for less invasive, more precise treatment options is only increasing. HistoSonics is answering this call with a technology that not only improves patient outcomes but also allows the surgeon to treat a wider variety of tumor types in the liver, kidney, pancreas, prostate, and even brain tumors. “Histotripsy is a paradigm-changing treatment option for patients who want a non-invasive approach to target and destroy tumors without the need for needles or incisions,” said Mike Blue, President & CEO, HistoSonics. “We’re thrilled to announce this top-tier investor syndicate led by Alpha Wave, which reinforces the confidence in our mission to impact patients’ lives with our current liver application and expanded use in kidney, pancreas, prostate, brain and other tumor types. With Alpha Wave Ventures leading the round, with support from Johnson & Johnson Innovation JJDC Inc, Amzak Capital Management and HealthQuest Capital. 🎉 Congratulations to the HistoSonics team on this funding.🎉 #medtech #noninvasivesurgery #innovation #investment #histotripsy #medicaltechnology

Lipid hard exudates can be particularly challenging in our patients with diabetic macular edema. A big thank you to Healio | Ocular Surgery News and Anthony DeFino and Eamon Dreisbach for covering our research looking at the efficacy of #faricimab in resolving hard exudates in the pivotal #yosemite and #rhine trials of patients with #DiabeticMacularEdema and #DiabeticRetinopathy. Kara Gibson PhD Manuel Amador, MD Florie Mar, PhD https://lnkd.in/ga-y9GHG

New episode 👉 #WeeklyPodcast Dr. Domenica Lorusso discussed the survival analysis of the #PAOLA1 trial 🎙️ https://bit.ly/4bf6DqJ #IJGConline #Research #Prevention #Treatment #Diagnostic #GynCancer #GynOnc #WomenHealth #SoMe #SoMe4GynOnc 🌟 Highlights 📌Bev+Olaparib has reported ⬆️ PFS and OS in advanced stIII-IV, newly diagnosed, high grade serous and endometrioid HRD+ #ovariancancer in the maintenance setting. 📌Exploratory analysis 🔍 suggest that the advantage is particularly high in low-risk patients (stIII without residual tumor at primary surgery), where a 5-y OS more than 90% has been reported suggesting some of these patients may be cured. 📌In the HRp population the combination of Olaparib+Bev did non increase PFS and OS in comparison to Bev alone. 📌The toxicity ☢️ profile of the combination is in line with what expected with the single drugs.

Lipid hard exudates can be particularly challenging in our patients with diabetic macular edema. A big thank you to Healio | Ocular Surgery News and Anthony DeFino and Eamon Dreisbach for covering our research looking at the efficacy of #faricimab in resolving hard exudates in the pivotal #yosemite and #rhine trials of patients with #DiabeticMacularEdema and #DiabeticRetinopathy. Kara Gibson PhD Manuel Amador, MD Florie Mar, PhD https://lnkd.in/ga-y9GHG

Lipid hard exudates can be particularly challenging in our patients with diabetic macular edema. A big thank you to Healio | Ocular Surgery News and Anthony DeFino and Eamon Dreisbach for covering our research looking at the efficacy of #faricimab in resolving hard exudates in the pivotal #yosemite and #rhine trials of patients with #DiabeticMacularEdema and #DiabeticRetinopathy. Kara Gibson PhD Manuel Amador, MD Florie Mar, PhD https://lnkd.in/ga-y9GHG

Lipid hard exudates can be particularly challenging in our patients with diabetic macular edema. A big thank you to Healio | Ocular Surgery News and Anthony DeFino and Eamon Dreisbach for covering our research looking at the efficacy of #faricimab in resolving hard exudates in the pivotal #yosemite and #rhine trials of patients with #DiabeticMacularEdema and #DiabeticRetinopathy. Kara Gibson PhD Manuel Amador, MD Florie Mar, PhD https://lnkd.in/ga-y9GHG